(58 days)
Not Found
No
The document describes software updates for linear accelerators and associated workspaces, focusing on patient data management, image processing, and treatment planning/delivery. There is no mention of AI or ML technologies being incorporated into these updates or the underlying systems. The performance studies described are standard software verification and validation tests, not studies typically associated with evaluating AI/ML model performance.
Yes
The intended use explicitly states that the device delivers radiation for the therapeutic treatment of cancer.
No
The device is primarily a linear accelerator system for therapeutic treatment of cancer, specifically for delivering X-ray photon and electron radiation. While its software includes tools to aid in "diagnosis, staging, and prescription of radiation therapy," its core function is treatment delivery, not solely diagnostic assessment.
No
The device is described as a software update to existing linear accelerator systems (ARTISTE, ONCOR, PRIMUS). While the submission focuses on the software update, the underlying device is a hardware-based linear accelerator system used for radiation therapy. The software functions as a control and processing component for this hardware.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is clearly stated as delivering radiation for the therapeutic treatment of cancer. This is a therapeutic device, not a diagnostic one.
- Device Description: The description focuses on the linear accelerator system and its software for patient setup, positioning, treatment delivery, and image processing for treatment planning and verification. These are all related to delivering therapy.
- No mention of in vitro testing: There is no indication that this device is used to examine specimens derived from the human body for the purpose of providing information for diagnosis, monitoring, or treatment.
IVD devices are used to perform tests on samples like blood, urine, or tissue outside of the body to diagnose or monitor conditions. This device is used to directly treat patients with radiation.
N/A
Intended Use / Indications for Use
The intended use of the SIEMENS branded ARTISTE™, ONCOR™ and PRIMUSTM family of linear accelerator systems is to deliver X-ray photon and electron radiation for the therapeutic treatment of cancer.
The linear accelerator systems are high-dose and high-dose rate medical linear accelerators optimized for 3D conformal radiation therapy, intensity-modulated radiation therapy (IMRT), modulated arc therapy (mARC) and precision stereotactic radiation therapy for lesions, turnors and conditions anywhere in the head and body where radiation therapy is indicated.
The syngo® workspaces includes a number of syngo® based, clinically focused advanced software applications that include patient data management, remote user communication within a local network, and the viewing, processing, manipulation, filming, and archiving of medical images.
The syngo® RT Therapist Workspace v4.3, contains software applications that permits patient selection/setup, patient positioning verification, treatment delivery/verification, and treatment recording. The syngo® RT Therapist Workspace v4.3, can be interfaced with third party devices conforming to the DICOM Standard.
The syngo® RT Oncologist Workspace v4.3 permits localization, contouring, segmentation, image calibration, and review of treatment plan parameters. In addition, it includes tools and administrative functions to aid in the diagnosis, staging, and prescription of radiation therapy.
Product codes (comma separated list FDA assigned to the subject device)
IYE
Device Description
The ARTISTE™ Solution SYS_VC10 is a software update to the ARTISTE family of medical linear accelerators and is intend to update customers with optional new fcatures for systems with the syngo® RT Therapist, v4.1 and RT Therapist Connect v4.2 Workspaces for the currently cleared ARTISTE systems. Additionally, the SYS VC10 software update also includes an (optional) software update for the syngo® RT Oncologist v4.2 workspace. The SYS VC10 update will bring the syngo® RT Therapist and the syngo® RT Oncologist workspaces to version 4.3.
This update is intended to be backwards compatible to the currently cleared ONCOR and PRIMUS family of medical linear accelerators and their Control Consoles (v9.0+ & v11.0. v12), the RT Therapist (v2.1a or v2.2+) and Oncologist v2.0 & v2.4 workspaces. These older versions can be migrated up to the current release (RTT / ONC. v4.3) and Control Console 13.
The technological characteristics and fundamental technology of the ARTISTE™ Solution remain unchanged from the currently cleared device (K103606).
The syngo® Suite for Oncology Workspace clinically focused software utilizes the proprietary syngo® software architecture design provides a method of delivering customized software applications based on the modality as clinically supporting packages. From these applications SIEMENS utilizes, as part of the Oncology clinical focus package, multiple applications for patient set-up and position verification, treatment localization, treatment verification, portal imaging as well as data processing, image reformatting, display and printing. The currently cleared COHERENCE™ and syngo® products also include an array of image-oriented software tools, support for DICOM connectivity and the Siemens Remote Service option.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
head and body
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Bench verification testing in the form of Unit (UT), Integration (IT), Sub-System Integration (SSIT), and System Integration (SIT) testing was performed to evaluate the performance and functionality of the new feature and software updates. All testable requirements have been successfully verified and traced in accordance with the Siemens product development (lifecycle) process (PDP).
The software verification and regression testing has been performed successfully to meet. their previously determined acceptance criteria as stated in the Test Plans.
Validation of the new features for syngo® RT Therapist Workspace, v4.3 and Oncologist v4.3 has been performed at the System test (ST) level on production prototype devices by appropriately trained and knowledgeable test personnel. System level validation and regression testing has been performed successfully, demonstrating that the software meets the acceptance criteria as noted in the system test plans and the Software Product Quality Management Plan (SwPQMP).
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Bench verification testing in the form of Unit (UT), Integration (IT), Sub-System Integration (SSIT), and System Integration (SIT) testing was performed to evaluate the performance and functionality of the new feature and software updates. All testable requirements have been successfully verified and traced in accordance with the Siemens product development (lifecycle) process (PDP). The software verification and regression testing has been performed successfully to meet their previously determined acceptance criteria as stated in the Test Plans. Validation of the new features for syngo® RT Therapist Workspace, v4.3 and Oncologist v4.3 has been performed at the System test (ST) level on production prototype devices by appropriately trained and knowledgeable test personnel. System level validation and regression testing has been performed successfully, demonstrating that the software meets the acceptance criteria as noted in the system test plans and the Software Product Quality Management Plan (SwPQMP).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K103606, K052315, K072916, K052423
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.5050 Medical charged-particle radiation therapy system.
(a)
Identification. A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.(b)
Classification. Class II. When intended for use as a quality control system, the film dosimetry system (film scanning system) included as an accessory to the device described in paragraph (a) of this section, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
Siemens Medical Solutions USA, Inc. Radiation Oncology
Section 5
JUN 2 7 2012
510(k) Summary
Date Prepared: Date Updated:
April 27, 2012 June 25, 2012
Page Sect. 5a/1
Submitter: Siemens Medical Solutions USA, Inc. Radiation Oncology 4040 Nelson Avenue Concord, CA 94520
Contact: Christine Dunbar Senior Manager, Regulatory Affairs
(925) 602-8157 Phone: Fax: (925) 602-8008 Email: christine.dunbar@siemens.com
Proprietary Name: ARTISTE™ Solution with SYS VC10
IYE
Medical Charged-Particle Radiation Therapy System Common Name:
Classification: 892.5050
Product Code:
Substantial Equivalence Claimed To:
| Product | 510(k) Clearance / Date | Claim of Equivalence for: |
|---|---|---|
| ARTISTE™ Solution with | ||
| SYS-VB50 update with | ||
| Control Console 12 & with | ||
| syngo® RTT Connect v4.2, | ||
| syngo® Oncologist v4.2 | K103606 / April 15, | |
| 2011 | ARTISTE™ Solution with SYS- | |
| VC10 update with Control | ||
| Console 13 & with syngo® RTT | ||
| v4.3, syngo® Oncologist v4.3 | ||
| SIMTEC IM MAXX 2 | ||
| Intensity Modulation | ||
| Radiation Therapy (IMRT) | K052315 / Sept. 22, | |
| 2005 | ARTISTE™ Solution with the | |
| SYS_VC10 & syngo® RT | ||
| Therapist v4.3 new feature | ||
| mARC | ||
| Varian Trilogy™ System | ||
| with RapidArc. | K072916 / Nov. 9, 2007 | ARTISTE™ Solution with the |
| SYS_VC10 & syngo® RT. | ||
| Therapist v4.3 with new feature |
510(k) for SIEMENS ARTISTE™ Solution with SYS_VC10
1
Siemens Medical Solutions USA. Inc. Radiation Oncology
| Product | 510(k) Clearance/ Date | Claim of Equivalence for: |
|---|---|---|
| Aka VMAT (volumetric | ||
| modulated arc therapy). | mARC (also called rotational | |
| IMRT) | ||
| syngo® Expert I option on | ||
| MAGNETOM Systems | K052423 / Jan. 13, | |
| 2006 | ARTISTE™ Solution with the | |
| SYS_VC10 & syngo® RT | ||
| Therapist v4.3. & Oncologist v4.3 | ||
| with new feature syngo® Expert i |
The ARTISTE™ Solution SYS VC10 Update as described in this premarket notification has the same intended use and fundamental scientific technical characteristics as the predicate devices, or specific features of the predicate devices listed above.
Description Summary - ARTISTE™ Solution with SYS_VC10 Update
Technological Characteristics:
The ARTISTE™ Solution SYS_VC10 is a software update to the ARTISTE family of
medical linear accelerators and is intend to update customers with optional new fcatures for systems with the syngo® RT Therapist, v4.1 and RT Therapist Connect v4.2 Workspaces for the currently cleared ARTISTE systems. Additionally, the SYS VC10 software update also includes an (optional) software update for the syngo® RT Oncologist v4.2 workspace. The SYS VC10 update will bring the syngo® RT Therapist and the syngo® RT Oncologist workspaces to version 4.3.
This update is intended to be backwards compatible to the currently cleared ONCOR and PRIMUS family of medical linear accelerators and their Control Consoles (v9.0+ & v11.0. v12), the RT Therapist (v2.1a or v2.2+) and Oncologist v2.0 & v2.4 workspaces. These older versions can be migrated up to the current release (RTT / ONC. v4.3) and Control Console 13.
The technological characteristics and fundamental technology of the ARTISTE™ Solution remain unchanged from the currently cleared device (K103606).
The syngo® Software Architecture:
The syngo® Suite for Oncology Workspace clinically focused software utilizes the proprietary syngo® software architecture design provides a method of delivering customized software applications based on the modality as clinically supporting packages. From these applications SIEMENS utilizes, as part of the Oncology clinical focus package, multiple applications for patient set-up and position verification, treatment localization, treatment verification, portal imaging as well as data processing, image
510(k) for SIEMENS ARTISTE™ Solution with SYS_VC10
Page Sect, 5a/2 :
0220
2
Siemens Medical Solutions USA, Inc. Radiation Oncology
reformatting, display and printing. The currently cleared COHERENCE™ and syngo® products also include an array of image-oriented software tools, support for DICOM connectivity and the Siemens Remote Service option.
General Safety and Effectiveness:
The device labeling contains instructions for use and any necessary cautions and warnings, to provide for safe and effective use of the device.
Risk management is ensured via a risk analysis, which is used to identify potential hazards and mitigations. These potential hazards are controlled by software means, user instructions, verification of requirements and validation of the clinical workflow to ensure that the product meets its intended uses. To minimize electrical, mechanical and radiation hazards, SIEMENS adheres to recognized and established industry practice and relevant international standards.
Intended Use:
The intended use of the SIEMENS branded ARTISTE™, ONCOR™ and PRIMUSTM family of linear accelerator systems is to deliver X-ray photon and electron radiation for the therapeutic treatment of cancer.
The linear accelerator systems are high-dose and high-dose rate medical linear accelerators optimized for 3D conformal radiation therapy, intensity-modulated radiation therapy (IMRT), modulated arc therapy (mARC) and precision stereotactic radiation therapy for lesions, turnors and conditions anywhere in the head and body where radiation therapy is indicated.
The syngo® Suite for Oncology Workspaces:
The syngo® workspaces includes a number of syngo® based, clinically focused advanced software applications that include patient data management, remote user communication within a local network, and the viewing, processing, manipulation, filming, and archiving of medical images.
The syngo® RT Therapist Workspace v4.3, contains software applications that permits patient selection/setup, patient positioning verification, treatment delivery/verification, and treatment recording. The syngo® RT Therapist Workspace v4.3, can be interfaced with third party devices conforming to the DICOM Standard.
The syngo® RT Oncologist Workspace v4.3 permits localization, contouring, segmentation, image calibration, and review of treatment plan parameters. In addition, it includes tools and administrative functions to aid in the diagnosis, staging, and . prescription of radiation therapy.
510(k) for SIEMENS ARTISTE™ Solution with SYS_VC10
Page Sect. 5a/3
0023
3
. Siemens Medical Solutions USA, Inc. Radiation Oncology
Substantial Equivalence:
The Substantial Equivalence comparison chart demonstrates the comparison of the technological characteristics of the new features and their currently cleared predicate devices.
The new features for the syngo® RTT and Oncologist Workspaces v4.3 does not change the intended use of the original syngo® RT Therapist or Oncologist Workspaces or the Siemens branded Linear Accelerator Systems.
Bench Testing:
Bench verification testing in the form of Unit (UT), Integration (IT), Sub-System Integration (SSIT), and System Integration (SIT) testing was performed to evaluate the performance and functionality of the new feature and software updates. All testable requirements have been successfully verified and traced in accordance with the Siemens product development (lifecycle) process (PDP).
The software verification and regression testing has been performed successfully to meet. their previously determined acceptance criteria as stated in the Test Plans.
Non-Clinical Test Results:
Validation of the new features for syngo® RT Therapist Workspace, v4.3 and Oncologist v4.3 has been performed at the System test (ST) level on production prototype devices by appropriately trained and knowledgeable test personnel. System level validation and regression testing has been performed successfully, demonstrating that the software meets the acceptance criteria as noted in the system test plans and the Software Product Quality Management Plan (SwPQMP).
Testing to Consensus Standards:
The Siemens branded Linear Accelerators with the new features have been tested to meet the requirements for conformity (where applicable) to multiple industry standards.
Substantial Equivalence to Predicates:
The successful verification and validation testing to the meet the new software features and device requirements of the syngo® RT Therapist and syngo® RT Oncologist workspaces software v4.3, in addition to the updated ARTISTE™ Solution Linear Accelerator functional requirements, is intended to support the claim of substantial equivalence to the currently cleared predicates as indicated above.
Summary: '
In summary, it is SIEMENS' opinion that the ARTISTE with the Sys VC10 update does not introduce any new potential safety risks and is substantially equivalent to, and performs as well as the predicate devices.
510(k) for SIEMENS ARTISTE™ Solution with SYS VC10
Page Sect. 5a/4
4
Image /page/4/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle or bird-like figure with three curved lines representing its wings or body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the emblem.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002
JUN 2 7 2012
Ms. Christine Dunbar Senior Manager, Regulatory Affairs Siemens Medical Solutions USA, Inc. Radiation Oncology 4040 Nelson Avenue CONCORD CA 94520
Re: K121295
Trade/Device Name: ARTISTE™ Solution with SYS_VC10 Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Regulatory Class: II Product Code: IYE Dated: April 27, 2012 Received: April 30, 2012
Dear Ms. Dunbar:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act that I Drines Intatutes and regulations administered by other Federal agencies. You must or any I with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
5
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely Yours,
Janine M. Morris
Acting Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
6
Siemens Medical Solutions USA, Inc. Radiation Oncology
Section 4
Indication for Use Statement
510(k) Number (if known): _ K121295
Device Name: ARTISTE™ Solution with SYS VC10
Indications for Use:
The intended use of the SIEMENS branded ARTISTE™, ONCOR™ and PRIMUS™ family of linear accelerator systems is to deliver X-ray photon and electron radiation for the therapeutic treatment of cancer.
The linear accelerator systems are high-dose rate medical linear accelerators optimized for 3D conformal radiation therapy, intensity-modulated radiation therapy (MRT), modulated are therapy (mARC) and precision stereotactic radiation therapy for lesions, turnors and conditions anywhere in the head and body where radiation therapy is indicated.
The syngo® Suite for Oncology Workspaces:
The syngo® workspaces includes a number of syngo® based, clinically focused advanced software applications that include patient data management, remote user communication within a local network, and the viewing, processing, manipulation, filming, and archiving of medical images.
The syngo® RT Therapist Workspace v4.3, contains software applications that permits patient selection/setup, patient position, treatment delivery/verification, and treatment recording. The syngo® RT Therapist Workspace v4.3, can be interfaced with third party devices conforming to the DICOM Standard.
The syngo® RT Oncologist Workspace v4.3 permits localization, contouring, segmentation, image review and review and approval of treatment plan parameters. In addition, it includes tools and administrative functions to aid in the diagnosis, staging, and prescription of radiation therapy.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
| Prescription Use | X | OR | Over-the-Counter Use | |
|---|---|---|---|---|
| (Per 21 CFR 801.109) |
(Division Sign-Off)
Division of Radiological Devices
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) for SIEMENS ARTISTE™ Solution with SYS_VC10
Page Sec0020